INNATE PHARMA SA-SPONS ADR (IPHA) Stock Price & Overview
NASDAQ:IPHA • US45781K2042
Current stock price
The current stock price of IPHA is 1.41 USD. Today IPHA is up by 2.92%. In the past month the price increased by 12.8%. In the past year, price decreased by -28.79%.
IPHA Key Statistics
- Market Cap
- 132.299M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.63
- Dividend Yield
- N/A
IPHA Stock Performance
IPHA Stock Chart
IPHA Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to IPHA. When comparing the yearly performance of all stocks, IPHA is a bad performer in the overall market: 87.85% of all stocks are doing better.
IPHA Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to IPHA. IPHA may be in some trouble as it scores bad on both profitability and health.
IPHA Earnings
On April 1, 2026 IPHA reported an EPS of -0.54 and a revenue of 2.79M. The company missed EPS expectations (-353.8% surprise) and beat revenue expectations (25.56% surprise).
IPHA Forecast & Estimates
8 analysts have analysed IPHA and the average price target is 7.01 USD. This implies a price increase of 397.4% is expected in the next year compared to the current price of 1.41.
For the next year, analysts expect an EPS growth of 13.33% and a revenue growth -2.22% for IPHA
IPHA Groups
Sector & Classification
IPHA Financial Highlights
Over the last trailing twelve months IPHA reported a non-GAAP Earnings per Share(EPS) of -0.63. The EPS increased by 10.35% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -78.41% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
IPHA Ownership
IPHA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.4 | 355.432B | ||
| AMGN | AMGEN INC | 15.09 | 188.147B | ||
| GILD | GILEAD SCIENCES INC | 14.75 | 165.877B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.09 | 110.672B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.03 | 80.984B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 44.76 | 41.869B | ||
| INSM | INSMED INC | N/A | 31.046B | ||
| NTRA | NATERA INC | N/A | 28.508B | ||
| BIIB | BIOGEN INC | 11.44 | 27.573B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 26.65B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.41 | 25.108B | ||
| MRNA | MODERNA INC | N/A | 20.96B | ||
| INCY | INCYTE CORP | 12.23 | 19B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About IPHA
Company Profile
Innate Pharma SA is a global, clinical-stage biotechnology company, which engages in developing immunotherapies for cancer patients. The company is headquartered in Marseille, Paca and currently employs 181 full-time employees. The company went IPO on 2006-10-31. The firm identifies and characterizes drug candidates, selects indications, and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of new therapeutic solutions and monoclonal antibodies for the treatment of cancer, as well as for the treatment of infectious diseases and chronic inflammatory pathologies. The firm develops two categories of immunotherapies: immuno-modulators and cytotoxic antibodies. The company works in collaboration with Bristol-Myers Squibb for Phase I cancer antibody program and with Novo Nordisk A/S for two antibody programs in inflammation treatment. The firm operates through anti-NKG2A antibody, an immune checkpoint inhibitor ready for Phase II development in oncology from Novo Nordisk. The company also has a multi-product partnership with AstraZeneca.
Company Info
IPO: 2006-10-31
INNATE PHARMA SA-SPONS ADR
117 avenue de Luminy, Bp 30191
Marseille PACA 13009 FR
CEO: Mondher Mahjoubi
Employees: 163
Phone: 33430303030
INNATE PHARMA SA-SPONS ADR / IPHA FAQ
What does INNATE PHARMA SA-SPONS ADR do?
Innate Pharma SA is a global, clinical-stage biotechnology company, which engages in developing immunotherapies for cancer patients. The company is headquartered in Marseille, Paca and currently employs 181 full-time employees. The company went IPO on 2006-10-31. The firm identifies and characterizes drug candidates, selects indications, and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of new therapeutic solutions and monoclonal antibodies for the treatment of cancer, as well as for the treatment of infectious diseases and chronic inflammatory pathologies. The firm develops two categories of immunotherapies: immuno-modulators and cytotoxic antibodies. The company works in collaboration with Bristol-Myers Squibb for Phase I cancer antibody program and with Novo Nordisk A/S for two antibody programs in inflammation treatment. The firm operates through anti-NKG2A antibody, an immune checkpoint inhibitor ready for Phase II development in oncology from Novo Nordisk. The company also has a multi-product partnership with AstraZeneca.
Can you provide the latest stock price for INNATE PHARMA SA-SPONS ADR?
The current stock price of IPHA is 1.41 USD. The price increased by 2.92% in the last trading session.
Does INNATE PHARMA SA-SPONS ADR pay dividends?
IPHA does not pay a dividend.
What is the ChartMill technical and fundamental rating of IPHA stock?
IPHA has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
How is the market expecting IPHA stock to perform?
8 analysts have analysed IPHA and the average price target is 7.01 USD. This implies a price increase of 397.4% is expected in the next year compared to the current price of 1.41.
What is INNATE PHARMA SA-SPONS ADR worth?
INNATE PHARMA SA-SPONS ADR (IPHA) has a market capitalization of 132.30M USD. This makes IPHA a Micro Cap stock.
Who owns INNATE PHARMA SA-SPONS ADR?
You can find the ownership structure of INNATE PHARMA SA-SPONS ADR (IPHA) on the Ownership tab.